Key result
Atrial fibrosis increases clot burden in patients with acute ischaemic stroke due to non-valvular atrial fibrillation (p<0.05), but does not correlate with thrombus physicochemical properties.
Why the study?
To investigate the effect of the degree of atrial fibrosis on clot burden score and thrombus physicochemical properties in patients with acute ischaemic stroke due to non-valvular atrial fibrillation.
Does atrial fibrosis affect clot burden score and physicochemical properties of thrombus in patients with acute ischaemic stroke due to non-valvular atrial fibrillation?
Observational (n=117)
No
Does atrial fibrosis affect clot burden score and physicochemical properties of thrombus in patients with acute ischaemic stroke due to non-valvular atrial fibrillation?
p-value: p=<0.05
Atrial fibrosis is associated with increased clot burden in patients with acute ischemic stroke due to non-valvular atrial fibrillation, but does not significantly correlate with thrombus composition or density.
Atrial fibrosis may flag higher clot burden in NVAF stroke; hypothesis-generating, requires prospective validation before clinical use.
Background: To investigate the effect of the degree of atrial fibrosis on the clot burden score (CBS) and physicochemical properties in patients with acute ischaemic stroke (AIS) due to non-valvular atrial fibrillation (NVAF). Methods: A total of 117 patients with AIS in NVAF attending the Department of Cardiovascular Medicine and the Cerebrovascular Diagnostic and Treatment Centre between August 2021 and May 2024 were included in the study. Baseline clinical data, biochemical indexes, and imaging data of the patients were collected, and the patients were divided into 93 cases of the CBS (score of 0-6) group and 24 cases of the CBS (score of 7-10) group according to the CBS. CBS (score of 0-6) signifies higher clot burden. The enzyme-linked immunosorbent assay was used to measure the concentration of galactaglutinin-3 (gal-3) and transforming growth factor (TGF-β1) in the serum of the patients, and the PTFV1 were collected by 12-lead electrocardiogram, and the differences in the degree of atrial fibrosis between different groups and the risk factors of CBS (score of 0-6) were analysed. To analyse the effect of atrial fibrosis on the collateral circulation of stroke, the patients were divided into 31 cases with good collateral circulation (grade 3-4) and 86 cases with poor collateral circulation (grade 0-2) according to the digital subtraction angiography (DSA) images. The cerebral thrombus was collected from 60 AIS patients who underwent mechanical thrombectomy. The content of erythrocyte, fibrin/platelets and leukocytes in the thrombus was analysed by Mathew's scarlet blue staining, and the density of thrombus was measured by computed tomography (CT). Results: -value < 0.05). Hypertension, proportion of CAF, homocysteine, NLR, D-dimer, uric acid, PTFV1 < -0.03 mm s, gal-3, and TGF-β1, were risk factors for the development of high CBS in atrial fibrillation (AF), and hypertension and CAF were the most important factors for the occurrence of AF in the independent risk factors for stroke combined with high clot burden. gal-3 and TGF-β1 were risk factors for poor collateral circulation, atrial fibrosis indexes were not associated with thrombus pathological composition and thrombus density. Conclusions: Atrial fibrosis increases clot burden in patients with AIS due to NVAF but does not significantly correlate with the physicochemical properties and density of the thrombus.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) conducted an observational in Acute ischaemic stroke due to non-valvular atrial fibrillation (n=117). Atrial fibrosis was evaluated on Clot burden score (CBS) and physicochemical properties of thrombus (p=<0.05). Atrial fibrosis increases clot burden in patients with acute ischaemic stroke due to non-valvular atrial fibrillation (p<0.05), but does not correlate with thrombus physicochemical properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: